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Abstract
N-linked glycans attached to specific amino acids of the gp120 envelope trimer of a HIV virion can modulate the binding
affinity of gp120 to CD4, influence coreceptor tropism, and play an important role in neutralising antibody responses.
Because of the challenges associated with crystallising fully glycosylated proteins, most structural investigations have
focused on describing the features of a non-glycosylated HIV-1 gp120 protein. Here, we use a computational approach to
determine the influence of N-linked glycans on the dynamics of the HIV-1 gp120 protein and, in particular, the V3 loop. We
compare the conformational dynamics of a non-glycosylated gp120 structure to that of two glycosylated gp120 structures,
one with a single, and a second with five, covalently linked high-mannose glycans. Our findings provide a clear illustration of
the significant effect that N-linked glycosylation has on the temporal and spatial properties of the underlying protein
structure. We find that glycans surrounding the V3 loop modulate its dynamics, conferring to the loop a marked propensity
towards a more narrow conformation relative to its non-glycosylated counterpart. The conformational effect on the V3 loop
provides further support for the suggestion that N-linked glycosylation plays a role in determining HIV-1 coreceptor
tropism.
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Introduction
The HIV-1 envelope (Env) glycoprotein plays a critical role in
the recognition, binding and entry of the virus to a new host cell
[1]. Upon recognition of the host target cell, the surface subunit
gp120 binds to the CD4 receptor and initiates a series of
conformational changes in the gp120 trimer that enables
subsequent binding to a chemokine coreceptor (CCR5 or
CXCR4), fusion of the HIV and host cellular membranes,
and entry into the cell. The HIV-1 envelope trimer, which
consists of three gp120-gp41 heterodimers, is heavily glycosy-
lated [2–5] and contains more than 75 potential N-linked
glycosylation sites [6]. The glycans are covalently linked to
specific asparagine residues of the envelope precursor protein
gp160 by the host cell machinery and are important for the
stabilisation and correct folding of gp120 [7,8]. Studies have
shown that N-linked glycans bound to the gp120 trimer form a
‘‘glycan shield’’ protecting the virus from neutralisation by the
host immune response [9–16]. More recently, a number of
studies have isolated broadly cross neutralising (BCN) antibodies
from HIV-infected individuals, the activity of which appears to
be highly dependent on the presence of glycosylation at a
number of positions on the gp120 trimer, particularly at position
332 (HXB2 numbering) [17–20].
Glycans have also been shown to increase the binding affinity of
gp120 for CD4, and the extent of glycosylation has been linked to
cellular coreceptor tropism [21–24]. Since viral coreceptor tropism
is associated with cell selection and disease progression, substantial
research has been undertaken to understand the differences
between viruses that preferentially use one, or both, of the
common chemokine coreceptors, CCR5 and CXCR4 [25–30].
Several regions of gp120 may influence coreceptor usage [31–39],
but features of the gp120 V3 loop in particular are recognised as
the key factors determining viral tropism [21,22,35–44]. These
factors include the net charge [21,45], mutations at particular
positions along the 35 amino acids of the V3 loop region
[40,42,44], and the presence or absence of an N-linked
glycosylation site [22,41–43]. The net charge and mutation profile
at specific sites of the V3 loop are commonly used in coreceptor
tropism prediction tools [44,46–48], however the role of the glycan
profile in determining tropism is less well understood. One of the
reasons for this is that the glycans of glycoproteins are challenging
structures to crystallise, and are therefore often excluded prior to
structural investigations. The heterogeneity in carbohydrate
composition and position, as well as their flexibility, inhibits
crystallisation, yet many glycoproteins are dependent on these
carbohydrates for folding into their native conformations [49,50].
Most of the currently available HIV-1 Env-related crystal
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structures are of a de-glycosylated gp120 monomer [51–53], with
recent studies describing a cryo-EM structure of the unliganded
trimeric Env precursor [54] as well as a partially glycosylated
gp120 in complex with antibodies and CD4 [55].
Molecular dynamics (MD) simulations can be used to comple-
ment experiment-based structural studies by providing insight into
spatial and temporal properties under physiological conditions
[56,57]. MD simulations are particularly suited to systems that are
experimentally underdetermined or poorly resolved, such as
glycans and glycoproteins [58], and can provide valuable insight
into the structure-function relationship of large biomolecular
systems. Two recent studies used MD simulations to describe the
conformational properties of gp120 and the gp120 V3 loop
[59,60], but did not address N-linked glycosylation directly.
Yokoyama et al. [59] focused on the potential role of the net
charge of the V3 loop, where one structure with a net charge of +7
and the other with a net charge of +3 was investigated. The MD
simulations of these gp120 structures led the authors to conclude
that the net charge of the V3 loop affects the structural dynamics
of the entire gp120 outer domain by modulating its electrostatic
potential [59]. In a separate study, MD simulations were carried
out on only the V3 loop regions of crystallised structures
originating from two viruses, one a CXCR4-using and the other
a CCR5-using virus [60]. The conclusions drawn therefore relate
to the coreceptor-specific dynamics of the V3 loop and the authors
suggest that an open V3 loop conformation supports X4-tropic
and a thinner conformation supports R5-tropic viruses.
Using MD simulations we can investigate the degree to which
glycans affect the structural fluctuations of the gp120 protein. In
this study we used molecular dynamics simulations to compare
glycosylated and non-glycosylated HIV-1 gp120 structures to
determine the influence glycans have on the mobility of the V3
loop of the glycoprotein.
Methods
Data Preparation
The crystal structure of the HIV-1 gp120 core including the V3
loop (PDB ID 2B4C [52]) was used as the starting structure for the
simulations. The published protein structure was crystallised in a
complex with CD4 and the X4 antibody; both of which were
removed. In order to allow direct comparison of our work with
that of Yokoyama et al. [59], who used the crystal structure 2B4C
as template, Gly 25 of the V3-loop (protein residue 322 of HXB2)
was mutated to arginine. The resulting G25R mutant had a net
charge of +3. During the pre-processing steps, both the N-
terminus (ACE; –COCH3) and the C-terminus (NME; –NHCH-3)
were capped to avoid introducing charges at these positions. This
non-glycosylated structure was used as control. For the glycosy-
lated structures, an online Glycoprotein Builder (http://www.
glycam.com), which is part of the GLYCAM Web-tools suite [12],
was used to build and covalently link a 3D structure of the high-
mannose glycan Man-9 (a-Manp-(1-2)-a-Manp-(1-6)-[a-Manp-(1-2)-
a-Manp-(1-3)]-a-Manp-(1-6)-[a-Manp-(1-2)-a-Manp-(1-2)-a-Manp-
(1-3)]-b-Manp-(1-4)-b-GlcpNAc-(1-4)-b-GlcpNAc, Man9GlcNAc2)
to specific N-glycosylation sites. Any steric clashes between glycans
or between a glycan and the protein were resolved manually by
rotating the phi (W), psi (Y), chi (X) torsions with the UCSF Chimera
package [61]. A mono-glycosylated structure was prepared with a
single Man-9 glycan linked at position 295 (glycosylated295), which is
located at the border of the V3 loop. This variant was created to
determine the extent to which proximity of N-linked glycans to the
V3 loop was enough to affect the structure or dynamic properties of
the loop. A second glycosylated variant (glycosylated5-glycans) was also
prepared, in which glycans were linked to five key asparagine
residues (295, 332, 339, 392, and 448) surrounding the V3 loop
[62-68]. These positions were identified in terms of their
relevance to coreceptor, CD4, or neutralising antibody binding
[62-68].
System Preparation
We used the tLEaP module of AMBER 10 [69] with the
AMBER ff99SB [70] force field for the protein, and GLY-
CAM06g [71] force field for the carbohydrates, to generate the
coordinate and topology files for both the glycosylated and the
non-glycosylated proteins. The topology files were converted for
use with the glycam2gmxRB.pl Perl script, kindly provided by Dr.
Marko Wehle, which enabled a mixed 1-4 non-bonded scaling
scheme to be used for the protein and carbohydrate force fields, as
recommended. [72–74]. GROMACS v4.07 [75,76] was used for
setting up the system, as well as for all simulations. The non-
glycosylated structure and glycosylated5-glycans structure were
immersed in a cubic water box of 16 nm3, whereas a cubic box
of 14 nm-
3 was defined for the glycosylated295 structure (the
smaller size was verified to be large enough for the protein to
remain immersed throughout the simulation). This solvation gave
rise to system sizes of 407880 atoms (non-glycosylated), 407934
atoms (glycosylated5-glycans), and 273457 atoms (glycosylated295).
The TIP3P explicit water model [77] was used for all simulations.
Chloride ions were added to neutralise each system, and all
electrostatic interactions were calculated within the Particle Mesh
Ewald (PME) approach [78]. Constraints on hydrogen-containing
bonds were imposed with the LINCS algorithm.
Simulations
Energy minimisation was performed on all systems for 100,000
steps using the steepest decent algorithm prior to the MD
simulations. All simulations were performed at 300 K. A step-
wise protocol was employed for equilibration, beginning with a
simulation under constant volume (NVT) conditions for 500 ps
followed by switching to constant pressure (NPT) conditions at 1
atm for a further 500 ps. During these steps the non-hydrogen
atoms were restrained with a force constant of 1000 kJ/mol/nm2.
Thereafter, the restraints were removed and the systems equili-
brated for a further 500 ps. A post-equilibration trajectory of 30 ns
with a time step of 1 fs was collected for each system. Three further
simulations of 10 ns each for the non-glycosylated and glycosy-
lated5-glycans structures were initiated from the 30 ns trajectories.
Starting structures were selected from snapshots taken at between
10 and 30 ns intervals, and these uncorrelated simulations were
used to demonstrate data reproducibility.
Analysis
In order to gain a better understanding of the differences in the
conformational propensity of the glycosylated and non-glycosylat-
ed gp120 proteins, the root mean square deviation (RMSD)
between the C-alpha atoms for each of the glycosylated and non-
glycosylated structures, relative to their corresponding initial
minimised structures was calculated using the g_rms function in
GROMACS [75,76]. Using g_rmsf we also calculated the root
mean square fluctuation (RMSF) for each C-alpha atom, where
the average structure generated over the 5 – 30 ns range of the of
the post-equilibration trajectory, was used as reference. The
distance between the centers of mass for different C-alpha atom
groups was calculated with the g_dist function. The distributions
of the distances between C-alpha atoms at the base of the V3-loop
(including the C-alpha atoms of amino acids 296–300 and 326–
331, HXB2 numbering) and at the tip of the loop (308–319,
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HXB2 numbering), as well as between the two sides of the V3 loop
(296–313 and 314–331, HXB2 numbering) for each trajectory
were determined. Apart from the distance between the commonly
defined regions of the base and tip [79], we also carried out an
analysis on additional regions of the base (positions 296, 297 and
331) and tip (positions 312 – 315) sections of the V3 loop, which
included the two cysteine C-alpha atoms as well one neighbouring
C-alpha atom at the base (three being the minimum that
constitutes a group for this calculation) and the C-alpha atoms
of the GPGR tip region. This allowed for the further investigation
into the movement of the extremes of the V3 loop. Principal
component analysis (PCA) was carried out using GROMACS
[75,76] with the g_covar and g_anaeig functions. General
statistical calculations were carried out in R [80]. Visual
inspections were carried out using the VMD [81] and the USCF
Chimera packages [61].
Results
The molecular dynamic simulations we performed in this study
allow us to illustrate the effect of N-linked glycosylation on the
dynamics of the HIV-1 gp120 protein with specific reference to the
V3 loop. A non-glycosylated structure (Figure 1A), a glycosylated
structure with five glycans (glycosylated5-glycans, Figure 1B) and a
glycosylated structure with a single glycan (glycosylated295, Figure
1C) were used for the comparisons. Given that the only difference
between the non-glycosylated and glycosylated gp120 structures
were the presence or absence of N-linked glycans bound to the
surface of the protein, we expect that any conformational
differences observed between the various structures are as a result
of the presence or absence of the glycans.
In order to gain a better understanding of the collective
dynamics of each individual structure, we plotted the RMSD
values for the C-alpha atoms of all structures across each 30 ns
trajectory (Figure S1). The RMSD plots illustrate the extent of
movement of each structure away from the initial corresponding
minimised starting structure at each time point on the trajectory.
The RMSD analyses provide an indication of the overall
conformational dynamics of the system and Figure S1 indicates
that for each system, the conformational equilibrium for the
protein backbone is reached after approximately 5 ns. The
subsequent analyses were carried out on the MD trajectories from
5 to 30 ns.
The RMSF profiles (Figure 2) illustrate the C-alpha atom
specific fluctuations for each MD simulation (averaging over 5–30
ns for each simulation). The plots show that the loop regions are
generally more dynamic than other more structured regions of the
protein (Figure 2). The C-alpha atom RMSF distribution for the
non-glycosylated MD simulation was significantly greater than
that of the glycosylated5-glycans- simulations (p , 0.05; one-sided
Wilcoxon rank-sum test), indicating that glycosylation dampens
the dynamics of the protein backbone. That glycosylation leads to
increased fold stability has been inferred experimentally [82,83]
and predicted theoretically [83,84], and is a generally accepted
phenomena. The C-alpha RMSF distribution of the non-
glycosylated simulation was also significantly greater than that of
the glycosylated295 --system (p , 0.05; one-sided Wilcoxon rank-
sum test), however no significant difference was found for the
comparison between the two glycosylated, glycosylated295 and
glycosylated5-glycans-, systems.
We also tested a further hypothesis that the effect of N-linked
glycans on the protein conformational dynamics may be additive,
and that the influence of a given glycan may affect only the regions
surrounding the N-linked glycosylation site. In this hypothesis, the
movement of the regions surrounding the glycans of the
glycosylated5-glycans- structure would be influenced more than that
of the equivalent regions of the glycosylated295- structure, but the
region immediately adjacent to the N-linked glycan at position 295
will be affected in the same way for each structure. In order to test
this, we compared the RMSF values for C-alpha atoms
surrounding position 295 for the non-glycosylated, glycosylated295
-and glycosylated
5-glycans
- structures. The distribution of the C-
alpha RMSF values 10 and 20 residues up- and downstream were
compared using the Wilcoxon rank sum test. No significant
Figure 1. The HIV-1 gp120 (PDB ID: 2B4C) structures used in this study. These are A) non-glycosylated, B) glycosylated5-glycans, and C)
glycosylated295, where the V3 loop of each structure can be seen extending out towards the bottom of each structure. D) A schematic representation
of the positions (HXB2 numbering) of the investigated N-linked glycosylation sites for the glycosylated5-glycans (red) and glycosylated295 (green)
structures. The ‘‘\\’’ denotes the missing V1-V2 loops.
doi:10.1371/journal.pone.0080301.g001
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differences were found (p . 0.05). We also compared the
distribution of RMSF values for the V3 loop of all three structures
and again, no significant differences were observed (p . 0.05).
In order to establish whether the dynamics of the V3 loop
depends on the glycan profile, we calculated the distribution of the
average distance between the centers of mass of the base and the
tip of the V3 loop for each system (Figures 3A and 3B). In
Figure 3A, the focus was on the commonly defined regions of
the base (including the C-alpha atoms of amino acids 296–300
and 326–331, HXB2 numbering) and the tip (308–319, HXB2
numbering) of the V3 loop [79]. We found a significant
difference (p , 0.001; Wilcoxon rank sum test) for all
comparisons (Figure 3A). The average distance between the
base and tip for the glycosylated295 V3 loop was significantly
larger than for the non-glycosylated and glycosylated5-glycans- V3
loops (Figure 3A), the latter two displaying similar distances. In
the second analysis (Figure 3B) we determined the average
distance between the centers of mass of the extreme groups of
the V3 loop base (positions 296, 297 and 331) and tip (positions
312 – 315). Similarly, in this case we found significant
differences for all comparisons of the non-glycosylated, glyco-
sylated295, and glycosylated5-glycans- structures (p , 0.001;
Wilcoxon rank sum test). However, although the average
distances for the glycosylated295 structure were still the largest,
in this case the distances for the glycosylated5-glycans- were visibly
shorter than for either of the other two structures (Figure 3B).
The comparisons between the distance distributions for the
extreme measurements (Figure 3B) may therefore offer a more
sensitive test for describing the movement of the V3 loop tip in
relation to the base, but it does not reveal the direction of the
movement. Since the first comparison (Figure 3A) included
amino acids adjacent to the stem of the V3 loop, it is possible
that the movement of the stem in relation to the base and tip
influenced these measurements. The stem residues on either side
of the loop may move in the same direction causing a bend in
the V3 loop, or they may move in the opposite directions
forming a bulge in the loop. Both these scenarios could result in
a shortening between the distance of the base and tip of the V3
loop, and this effect would be more amplified when focusing on
the extremes of the base and tip.
To probe variations in loop topology further, we compared the
distribution of the average distance between the centers of mass of
the two sides of the V3 loop (residues 296–313 and 314–331,
HXB2 numbering) for all systems (Figure 3C). The difference
between the distance distributions for the all the combinations of
comparisons between the non-glycosylated, glycosylated5-glycans-
-and glycosylated
295 was highly significant (p , 0.001; Wilcoxon
rank sum test; Figure 3C). However, the average side-to-side
distance for the non-glycosylated loop structure was larger than
seen in either of the glycosylated forms (Figure 3C). These results,
together with the observations for the comparison of the distances
between the base and tip, suggest that the glycosylated295 structure
takes on a narrow elongated shape, while the glycosylated5-glycans-
takes on a narrow but bent shape (given the shorter average base-
tip distance). A visual representation of the average shape of the
V3 loop for each trajectory also supported this hypothesis (Figure
3D, using 5–30 ns). The V3 loop of the non-glycosylated structure
had a much broader conformation with the two sides of the loop
forming a bulge, whereas the glycosylated structures on the other
hand showed a preference for a more narrow conformation
(Figure 3D). However, the average shape does not necessarily
provide a meaningful representation of the underlying dynamics of
the system. Furthermore, although the distributions of distances
provide an indication of the movements across the trajectories,
these distances include the high frequency movements that
contribute to the background noise.
Principal component analysis (PCA) was carried out to describe
the predominant movement of the V3 loop for each of the three
MD simulations. PCA produces several principal components that
describe a proportion of the system variance. For each of our
structures, the first principal component (PC1) described 41%,
47% and 37% of the motion of the V3 loop for the non-
Figure 2. RMSF values for the C-alpha atoms. These values represent the entire gp120 protein (based on the amino acid sequence of PDB ID:
2B4C) for the non-glycosylated, glycosylated5-glycans, and glycosylated295 trajectories. The conserved and variable regions of HIV-1 gp120 are marked,
and the ‘‘\\’’ denotes the missing V1-V2 loops.
doi:10.1371/journal.pone.0080301.g002
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glycosylated, glycosylated5-glycans- -and glycosylated
295, forms
respectively (Table 1). We found that the first three principal
components incorporated the majority of the movement for each
system, and collectively describe 63% (non-glycosylated), 73%
(glycosylated5-glycans) and 70% (glycosylated295) of the total motion
of each system (Table 1). In order to visualise the variance
described by each principal component, we plotted the extremes,
and intermediate, positions of each motion (Figure 4, and Figures
S2 and S3). These representation of each of the three principal
components were generally consistent with the results from the
distance calculation where the V3 loop of the non-glycosylated
structure takes on an open, broader, shape (Figure 4B) and the V3
loop of the glycosylated5-glycans- structure has a more narrow and
bent shape (Figure 4C). The V3 loop in the glycosylated295
structure also takes on a more narrow shape, but appears to
fluctuate between elongated and bent conformations (Figure 4D).
This may indicate that the additional glycans in the glycosylated5-
glycans form may be stabilising the bent topology.
In order to confirm that the results obtained from the analysis of
the 30 ns trajectories were not derived from the systems
populating local minima, we repeated the V3 loop analyses on
three additional 10 ns simulations (started from uncorrelated
snapshots) for each of the non-glycosylated and glycosylated5-
glycans systems. Apart from one calculation, the comparisons of
the distributions of the average distance between the centers of
mass of the base and the tip (both for the defined regions, Figure
S4A, as well as the extremes, Figure S4B) of the V3 loop were
highly significant (p , 0.001; Wilcoxon rank sum test). The
comparisons between the distributions of the average distance
between the centers of mass of the two sides of the V3 loop
(residues 296–313 and 314–331, HXB2 numbering) for each
trajectory, was highly significant (Figure S4C, p , 0.001;
Wilcoxon rank sum test). These results, together with the
representation of the average structures for each of the 10 ns
simulations (Figure S4D), are in agreement with the initial
findings (30 ns trajectory results) where the glycosylated5-glycans
V3 loops is more narrow than the non-glycosylated form.
The PCA of the uncorrelated snapshots MD simulations
showed that the first three principal components described
between 65% and 81% of the variance for each system (Table
S1). The images representing the extremes, and intermediate,
positions of each motion (Figures S5, S6 and S7) followed the same
trend as seen with the PCA based on the 30 ns trajectories of the
non-glycosylated and glycosylated5-glycans structures. Indeed, the V3
loop of the non-glycosylated system favours a much broader shape
(Figures S5B, S6B and S7B) compared to the glycosylated5-glycans-
Figure 3. Comparison between distance distributions for regions of the V3 loop. Comparison between the distance distributions for the
centers of mass between the base and tip of the V3 loop (A and B) and between the two sides of the V3 loop (C); and the corresponding average V3
loop structures (D) using 5–30 ns of the trajectories for the non-glycosylated (blue), glycosylated5-glycans- (red) -and glycosylated295 (green) examples.
doi:10.1371/journal.pone.0080301.g003
Table 1. Percentage motion included in each of the first
three, and the total sum of the first three, principal
components (PCs).
PC1 (%) PC2 (%) PC3 (%) Total (%)
Non-glycosylated 41 13 9 63
Glycosylated5-glycans 47 17 9 73
Glycosylated295 37 25 8 70
doi:10.1371/journal.pone.0080301.t001
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structures, which appear to prefer narrower and bent loops (Figures
S5C, S6C and S7C).
Discussion
In this study we have investigated the impact of N-linked
glycans on the dynamics of the HIV-1 gp120 protein with specific
reference to the V3 loop. The dynamic properties of HIV-1
envelope proteins play an important role in the successful binding
and transmission of a virion to a host cell [85,86]. Two recent
studies have used molecular dynamic simulations to describe the
movement of gp120 and the gp120 V3 loop [59,60], however the
influence of glycans on the underlying movement was not explicitly
addressed. Such structural studies are important to further our
understanding of the dynamic interaction between HIV-1 gp120,
the CD4 receptor and coreceptors. They also allow us to associate
the observed dynamics with known sequence and chemical features
of the V3 loop that play a role in determining coreceptor usage.
These features are commonly used in coreceptor prediction tools
and include specific amino acid mutations at particular positions of
the V3 loop as well as the net charge [21,22,41-44,47,48,87,88].
The presence or absence of an N-linked glycosylation site within the
V3 loop has also been reported to influence coreceptor tropism
[22,43], but little is known about the mode of this action. Here we
used molecular dynamic simulations to describe the dynamics of the
V3 loop with and without taking the potential influence of N-linked
glycans into account.
Our findings suggest that the presence of N-linked glycans has a
significant impact on the dynamics of the gp120 protein
particularly on the movement and preferred conformation of the
V3 loop. Differences in both the length of the loop, as well as its
side-to-side separation, were observed as a function of glycosyl-
ation pattern. The average distance between the base and the tip
of the V3 loop for all three structures provided a first look at the
potential influence of a given glycan profile, and we observed a
significant difference for all combinations of comparisons between
the non-glycosylated, glycosylated295 and glycosylated5-glycans
structures. However, the clear difference in distances between
the two sides of the V3 loop illustrated the considerable extent to
which glycans may be affecting the conformation of the loop. The
V3 loop of the glycosylated structures took on a significantly more
narrow formation compared to that of the non-glycosylated form.
The side-to-side distances together with the base-tip distances
suggested that the V3 loop of the non-glycosylated structure took
on an open, broader, shape, the V3 loop of the glycosylated5-glycans
structure was more narrow and bent, and the V3 loop of the
glycosylated295 structure was narrow but more elongated (Figure
3D). These observations were further substantiated by the results
for the additional non-glycosylated and glycosylated 5-glycans
examples (three uncorrelated simulations of 10ns each, Figure
S4D) where the same trend was seen.
The results from the principal component analysis further show
a clear difference between the coordinate space most commonly
occupied by the non-glycosylated, glycosylated295 and glycosylat-
ed5-glycans systems (Figure 4, and Figures S2 and S3). The glycans
appear to constrain the breadth of movement of the V3 loop, with
the tip of the loop, in particular, appearing to move actively away
from the glycans. Where a single glycan adjacent to the V3 loop
was present (glycosylated295) this observation was less distinct than
for the structure with five glycans attached (glycosylated5-glycans).
For the glycosylated295 structure the V3 loop fluctuated between
an elongated and bent shape, and therefore the tip appeared to
move away from the glycan intermittently (Figure 4D). In contrast,
the V3 loop for the glycosylated5-glycans structure remained in a
more bent conformation with the tip moving away from the
glycans consistently (Figure 4C). The significant difference
observed between the RMSF distribution of the C-alpha atoms
for the entire gp120 protein for the non-glycosylated and
glycosylated structures (Figure 2) may suggests that the glycan
surface density plays a role in the fluctuation of nearby atoms and
residues. In this case, steric hindrance imposed by the N-linked
glycans, or the additional weight contribution from the N-linked
glycans, could affect the surrounding protein structure. If this is the
case then the type and size of each glycan could further influence
the fluctuation of the protein regions neighbouring N-linked
glycosylation sites. However, we did not observe a significant
difference between the fluctuations of the C-alpha atoms
bordering the N-linked glycosylation site at position 295 for the
glycosylated295 and the non-glycosylated forms, which may suggest
that not all protein regions are as susceptible to a change in
dynamics as loop regions may be. This may also reflect the
relatively limited sampling of backbone conformations accessible
to a 30 ns simulation. A previous study by Yokoyama et al. [59]
also remarked that no significant change was observed in their
MD simulations when a high mannose glycan was present in the
V3 loop compared to when the glycan was absent, although no
reference was given to the position of the added glycan. Future
investigations will need to be carried out to determine whether any
single glycan attached at an N-linked glycosylation site has a
significant impact on the mobility of the protein.
The underlying amino acid sequences of the protein structures
we used were identical and only the glycan profile differed
between examples. [60]. The observation that the non-glycosylat-
ed example of the V3 loop takes on an open, broader form and the
Figure 4. Representation of the range of movement of the V3 loops for the first principal component. The range of movement is
presented for (A) all systems, (B) non-glycosylated, (C) glycosylated5-glycans, and (D) glycosylated295 trajectories. The shaded colors represent the
intermediate positions between the extremes.
doi:10.1371/journal.pone.0080301.g004
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glycosylated forms thinner, elongated/bent shapes can therefore
only be associated with the extent of glycosylation and not tropism.
This is in contrast to a previous study where the authors used MD
simulations to characterise the movement of the V3 loop regions of
crystallised structures originating from two viruses, one a CXCR4-
using and the other a CCR5-using virus [60]. In their study, where
the V3 loop sequence for each structure was unique, the authors
suggested that an open V3 loop conformation supports X4-tropic
and a thinner conformation supports R5-tropic viruses [60]. We
suggest, therefore, that both the underlying amino acid sequence
as well as the glycosylation profile impacts the molecular dynamics
of the gp120 protein and that both factors must be considered in
future structural analyses.
One of the major obstacles related to HIV-1 gp120 structural
investigations relates to the availability of high-resolution crystal
structures that include the variable loops. Here, we have used the
2B4C gp120 crystal structure, which includes the V3 loop, to enable
comparison with previous reports that used the same structure for
MD simulations [59,60]. Furthermore, previous studies have shown
that the functions of the gp120 core are somewhat independent of
the variable loops in that, regardless of the underlying amino acid
sequence, it retains its fundamental structural characteristics and
ligand binding capacity despite the absence of the variable loops
[89,90]. Therefore we expect that the core structure derived from
the crystal will have a minor influence on the overall outcome of the
molecular dynamic simulations relative to that of the underlying
amino acid sequence and glycan composition. The loop regions of a
protein are also highly dynamic [91] and therefore difficult to
crystallise [92], and it is likely that the configuration of the gp120
variable loops in the crystal structure represents only one of the
many possible conformations. Molecular dynamic techniques
generate multiple ensembles of the variable loops and the ongoing
refinement of the force field parameters will continue to improve the
accuracy of the methods to describe the conformational properties
of proteins [93-95].
A recent study describes the differences in the crystal structures
of the CCR5 and CXCR4 chemokine receptors and suggests that
the steric hindrances due to amino acid substitutions may present
one of the major factors involved in HIV-1 coreceptor selection [96].
Given the results from our study, we hypothesise that the steric
hindrances imposed by N-linked glycans may present a further
determinant of coreceptor usage. While the focus of this study was
not specifically to identify the structural determinants of coreceptor
usage, our results suggest that future studies should focus on
exploring the interplay between the underlying amino acid sequence
and the glycan composition in determining coreceptor tropism.
The importance of N-linked glycosylation of gp120 is not only
evident in coreceptor studies, but they also play a role in HIV-1
antibody neutralisation and escape [9]. Because the intracellular
glycosylation process, which adds the glycans to proteins, is that of
the host, the immune system does not recognise the viral glycans as
non-self, thereby allowing the virus to escape antibody driven
responses [97]. It has also been shown that N-linked glycans
bound to the surface of HIV-1 gp120 form part of several
important neutralising antibody epitopes and the removal of even
a single glycan can completely abolish a neutralising antibody
response [17,19,20]. Our initial glycoprotein modelling results
allude to not only a protein-glycan interaction, but also a glycan-
glycan interaction, in such that the movement and influence of a
single glycan is affected by the presence and mobility of a second
glycan at an adjacent N-linked glycosylation site. This further
underlines the importance of broadening our understanding of the
influence that N-linked glycans have on the various regions of
HIV-1 gp120.
Our molecular dynamics results clearly illustrate the importance
of taking the glycan profile of HIV-1 gp120 into account during
structural investigations. Describing the temporal and spatial
constraints affecting the dynamics of different regions of gp120
may provide key insight into the structural features that drive HIV
evolution and allow the virus to switch between using the CXCR4
and CCR5 coreceptor for cell entry. Furthermore, these analyses
will add to our understanding of how we can take advantage of
these protective and adaptive characteristics to guide the design of
carbohydrate-binding HIV therapies.
Supporting Information
Figure S1 RMSF values for the C-alpha atoms. These values
represent the entire gp120 for the non-glycosylated, glycosy-
lated5-glycans, and glycosylated295 trajectories. The shaded areas
represent the part of the trajectory that was discarded as burn-in.
(TIF)
Figure S2 Representation of the range of movement of the V3
loops for the second principal component. The range of
movement is presented for (A) all systems, (B) non-glycosylated,
(C) glycosylated5-glycans, and (D) glycosylated295 trajectories. The
shaded colors represent the intermediate positions between the
extremes.
(TIF)
Figure S3 Representation of the range of movement of the V3
loops for the third principal component. The range of movement
is presented for (A) all systems, (B) non-glycosylated, (C)
glycosylated5-glycans, and (D) glycosylated295 trajectories. The
shaded colors represent the intermediate positions between the
extremes.
(TIF)
Figure S4 Comparison between distance distributions for
regions of the V3 loop. Comparison between the distance
distributions for the centers of mass between the base and tip of
the V3 loop (A and B) and between the two sides of the V3 loop
(C); and the corresponding average V3 loop structures (D) using
the entire 10 ns of the uncorrelated trajectories for the three non-
glycosylated (blue) and three glycosylated5-glycans- (red) additional
examples.
(TIF)
Figure S5 Representation of the range of movement of the V3
loops for the first principal component. The range of movement is
presented for (A) non-glycosylated and glycosylated5-glycans, (B)
non-glycosylated, and (C) glycosylated5-glycans trajectories. The
shaded colors represent the intermediate positions between the
extremes.
(TIF)
Figure S6 Representation of the range of movement of the V3
loops for the second principal component. The range of
movement is presented for (A) non-glycosylated and glycosylat-
ed5-glycans, (B) non-glycosylated, and (C) glycosylated5-glycans
trajectories. The shaded colors represent the intermediate
positions between the extremes.
(TIF)
Figure S7 Representation of the range of movement of the V3
loops for the third principal component. The range of movement
is presented for (A) non-glycosylated and glycosylated5-glycans, (B)
non-glycosylated, and (C) glycosylated5-glycans trajectories. The
shaded colors represent the intermediate positions between the
extremes.
(TIF)
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Table S1 Percentage motion included in each of the first three,
and the total sum of the first three, principal components (PCs) for
each of the uncorrelated repeats (10 ns).
(PDF)
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